



COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

1st Congress
June 22, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-6791

EMAIL:
Info@ISVCONGRESS.ORG

Program June 22, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions
Chairs: Linda Klavinskis & Shan Lu, ISV

Opening Session (20 min talks + 5 min Q&A)

Overview, Chair: Shan Lu, ISV

9:05am Kwok-Yung Yuen, The University of Hong Kong
Overview of COVID-19

9:30am Nick Jackson, CEPI
Overview of COVID-19 vaccine development

Scientific Session One (18 min talks + 7 min Q&A)

Nucleic Acid Vaccines, Chair: Margaret Liu, ISV

9:55am Kate Broderick, Inovio Pharmaceuticals
Advantages of a DNA-based Approach to the
Development of a COVID-19 Vaccine

10:20am Barney Graham (VRC/NIAID/NIH)
Rapid COVID-19 Vaccine Development Enabled
by Prototype Pathogen Preparedness

Viral Vector Vaccines, Chair: Linda Klavinskis, ISV

10:45am Sarah Gilbert, University of Oxford
Rapid Progress with Development of ChAdOx1
nCoV-19

11:10am Tao Zhu, CanSino Biological
Development of Adenovirus Vector based
COVID-19 Vaccine

Scientific Session Two (25 min panel discussion)

Challenges for COVID-19 vaccines development

Moderator: David Weiner, ISV

11:35am Peter Openshaw, Imperial College London
Stanley Perlman, University of Iowa
Stanley Plotkin, VaxConsult

- Are human challenge studies acceptable?
- Safety concerns and suboptimal antibody responses

Wrap up and announcement of 2nd ISV Virtual Congress on COVID-19 Vaccines

12 noon Closing remarks
Margaret Liu, ISV

The virtual congress will be run by Microsoft Teams.





COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

2nd Congress
July 21, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Program July 21, 9:00am – 12:00PM (ET)

9:00 am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King's College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Denise Doolan, James Cook University/ISV
9:05am Larry Corey, Fred Hutchinson Cancer Res. Center
COVID Vaccine Planning: The USG Approach
9:30am Marion Gruber, US FDA
Regulatory Considerations in the Development
and Licensure of COVID-19 Vaccines

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein and Inactivated Vaccines

Chair: Manon Cox, NextWaveBio/ISV
9:55am Greg Glenn, Novavax
Progress with the Full Length Recombinant Spike
Protein Nanoparticle Vaccine
10:20am George Gao, China CDC
Development of Inactivated COVID-19 Vaccines

Part II: Viral Vector and RNA Vaccines

Chair: Linda Klavinskis, King's College London/ISV
10:45am Hanneke Schuitemaker, J&J/Janssen
The Development of an Ad26-based
SARS-CoV-2 Vaccine
11:10am Kena Swanson, Pfizer
RNA Based COVID-19 Vaccines

Scientific Session Two (25 min panel discussion)

Challenges for COVID-19 Vaccines Development:

The Roles of Animal Models

Moderator: Stanley Perlman, University of Iowa
11:35am Bart Haagmans, Erasmus University
Vincent Munster, RML/NIH
Linda Saif, The Ohio State University

Wrap up and Announcement of 3rd ISV Virtual Congress on COVID-19 Vaccines

12:00PM Shan Lu, ISV

ISV Virtual Congress Series Co-Chairs
Linda Klavinskis, Margaret Liu, Shan Lu / ISV
Senior Advisor
Nick Jackson / CEPI





COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

3rd Congress
Aug 25, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Program Aug 25, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King's College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Shan Lu, ISV
9:05am Myron Cohen, UNC-Chapel Hill
mAbs for COVID-19: Treatment and Prevention
9:30am Lynda Stuart, Bill & Melinda Gates Foundation
COVID-19 Vaccine: How We Win the Race to
Billions of Doses

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein Vaccines

Chair: Xavier Saelens, University of Ghent/ISV
9:55am Keith Chappell, The University of Queensland
Molecular Clamp Stabilized Recombinant Protein
Subunit Vaccine for COVID-19
10:20am John Shiver, Sanofi-GSK
Recombinant and mRNA Vaccine Candidates
Against COVID-19

Part II: Novel Vaccine Technologies

Chair: Anna-Lise Williamson, University of Cape Town/ISV
10:45am Jacqueline Miller, Moderna
Moderna's Coronavirus Vaccine: Early Clinical Data
and the COVE Phase III Efficacy and Safety Study
11:05am Brian Ward, Medicago
Development of Plant-Derived SARS-CoV-2 Virus-
Like Particle (CoVLP) Vaccine

Scientific Session Two (30 min panel discussion)

The Role of T and B Cell Responses and Vaccine Assay Standards
for Determining Efficacy

Moderator: Margret Liu, ProTherImmune/ISV
11:30am Alessandro Sette, La Jolla Institute for Immunology
Michel Nussenzweig, The Rockefeller University
Neil Almond, NIBSC

Wrap up and Future ISV Virtual Congresses

12:00pm Linda Klavinskis, ISV

ISV Virtual Congress Series Co-Chairs

Linda Klavinskis, Margaret Liu, Shan Lu / ISV
Senior Advisors

Nick Jackson / CEPI, Susan Barnett / BMGF





COVID-19 VACCINE UPDATE

2021 ISV VIRTUAL CONGRESS

Feb 10, 2021

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Program Feb 10, 8:55am – 11:35am (ET)

8:55am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Introduction Linda Klavinskis, King's College London/ISV

Session One: Adeno Viral Vector Vaccines

Chair: Linda Klavinskis, ISV

9:00am Inna Dolzhikova, Gamaleya National Research Center for Epidemiology and Microbiology
Safety and Efficacy of Sputnik V Vaccine:
An Interim Analysis of Phase 3 Trial in Russia

9:30am Sarah Gilbert, Oxford University/AZ
Pandemic Vaccine Development During a Pandemic

Session Two: mRNA Vaccines

Chair: Margaret Liu, ProTherImmune/ISV

10:00am Kathrin Jansen, Pfizer
Efficacy Data Updates from the Pfizer-BioNTech mRNA Vaccine Candidate

10:30am Jacqueline Miller, Moderna
Overview of the Moderna COVID-19 Vaccine (mRNA-1273)

Session Three: Post-Authorization Safety Surveillance

Chair: Shan Lu, ISV

11:00am Tom Shimabukuro, US CDC
COVID-19 Vaccine Safety Update, United States

Wrap up and Future ISV Virtual Congresses

11:30am Shan Lu, ISV

Congress Advisors

Yiwu He, The University of Hong Kong (HKU)
Nick Jackson, The Coalition for Epidemic Preparedness Innovations (CEPI)
Merlin Robb, U.S. Military HIV Research Program (MHRP)
Nina Russel, Bill & Melinda Gates Foundation (BMGF)





5TH COVID-19 VACCINE UPDATE

2021 ISV VIRTUAL CONGRESS

April 27 USA/April 28 China

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Scientific Program

April 28, 8:30 am – 10:20 am (Beijing time)

8:30am Welcome and Introductions
Chair: Shan Lu, U Mass Medical School/ISV
Introduction Denise Doolan, President-Elect ISV

Session One: Adenoviral Vector Based Vaccine

Chair: Denise Doolan, James Cook University/ISV
8:40am Jinbo Gou, CanSino Biological
Updates on Recombinant Adenovirus 5 vector based
COVID-19 Vaccine (Ad5-nCoV)

Session Two: Inactivated Vaccines

Chair: Joon Rhee, Chonnam Nat. Uni Med School/ISV
9:10am Meng Li
Sinopharm CNBG
Phase III Study of Inactivated COVID-19 Vaccine
9:40am Weining Meng
Sinovac Biotech Co., Ltd.
Phase III Clinical and Real-World Data of Inactivated
COVID-19 Vaccine

Wrap up and Future ISV Virtual Congresses

10:10am Shan Lu, U Mass Medical School/ISV

Congress Advisors

Yiwu He, University of Hong Kong (HKU)
Nick Jackson, Coalition for Epidemic Preparedness
Innovations (CEPI)

April 28, 2021

Sydney 10:30 am
Seoul/Tokyo 9:30 am
Beijing 8:30 am
New Delhi 6:30am
Frankfurt 2:30am
London 1:30 am

April 27, 2021

New York 8:30pm
Los Angeles 5:30pm



6TH COVID-19 VACCINE UPDATE

2021 ISV VIRTUAL CONGRESS

May 25

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Scientific Program

May 25, 9:00AM – 11:35AM (EDT)

9:00am Welcome and Introductions
Chair: Shan Lu, U Mass Medical School/ISV
Introduction Linda Klavinskis, King's College London/ISV

Session One: Adeno Vector COVID-19 Vaccine Update

Chair: Linda Klavinskis, King's College London/ISV
9:10am Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V.
Janssen's Effort in the Development of a COVID-19 Vaccine

Session Two: Recombinant Protein COVID-19 Vaccine Update

Chair: Margaret Liu, ProTherImmune/ISV
9:50am Greg Glenn, Novavax, Inc.
COVID-19 Program Update

Session Three: Vaccine Variants

Chair: Shan Lu, U Mass Medical School/ISV
10:30am Pei-Yong Shi, U of Texas Medical Branch
SARS-CoV-2 Variants and Antibody Neutralization

Session Four: Vaccine Safety

Chair: Shan Lu, U Mass Medical School/ISV
11:00am Mariana Castells, Brigham and Women's Hospital
COVID-19 mRNA Vaccine Safety: Local and Systemic Hypersensitivity

Wrap Up and Future ISV Virtual Congresses

11:30am Margaret Liu, ProTherImmune/ISV

Congress Advisors

Nick Jackson, Coalition for Epidemic Preparedness Innovations (CEPI)

May 25, 2021

New York 9:00 am
Los Angeles 6:00 am
London 2:00 pm
Frankfurt 3:00 pm
Beijing 9:00 pm
Seoul/Tokyo 10:00 pm

